Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. April 2021 20:00 ET | Quelle: GW Pharmaceuticals plc

GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation

LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising regulatory...
23. April 2021 16:01 ET | Quelle: GW Pharmaceuticals plc

GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals

LONDON and DUBLIN, April 23, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to...
20. April 2021 06:30 ET | Quelle: GW Pharmaceuticals plc

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex

– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to...
13. April 2021 08:30 ET | Quelle: GW Pharmaceuticals plc

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies Nabiximols data show efficacy and...
26. Februar 2021 07:15 ET | Quelle: GW Pharmaceuticals plc

GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved...
16. Februar 2021 07:00 ET | Quelle: GW Pharmaceuticals plc

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress

– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year – – Total Epidiolex® net product sales of $144.1 million for the fourth quarter and $510.5 million for...
11. Januar 2021 07:00 ET | Quelle: GW Pharmaceuticals plc

GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year -- Total Epidiolex® preliminary net product sales of...
05. Januar 2021 12:24 ET | Quelle: GW Pharmaceuticals plc

CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group) under the same headline,...
05. Januar 2021 07:30 ET | Quelle: GW Pharmaceuticals plc

GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and...
21. Dezember 2020 11:30 ET | Quelle: GW Pharmaceuticals plc

JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex

CARLSBAD, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of...

Nächste Seite